Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.